Copyright
©The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jun 14, 2017; 23(22): 4054-4063
Published online Jun 14, 2017. doi: 10.3748/wjg.v23.i22.4054
Published online Jun 14, 2017. doi: 10.3748/wjg.v23.i22.4054
Barcelona Clinic Liver Cancer outperforms Hong Kong Liver Cancer staging of hepatocellular carcinoma in multiethnic Asians: Real-world perspective
James Weiquan Li, Boon-Bee George Goh, Pik-Eu Chang, Chee-Kiat Tan, Department of Gastroenterology and Hepatology, Singapore 169856, Singapore
Boon-Bee George Goh, Pik-Eu Chang, Chee-Kiat Tan, Duke-NUS Medical School, 8 College Road, Singapore 169857, Singapore
Author contributions: Li JW designed and performed the research and wrote the paper; Goh BBG performed the research, provided writing advice and supervised the paper; Chang PE provided writing advice and supervised the paper; Tan CK performed the research, helped with the writing of the manuscript and supervised the paper.
Institutional review board statement: This study was reviewed and approved by the Institutional Review Board (IRB), Singapore Health Services.
Informed consent statement: The IRB approved waiver of consent as the clinical data was anonymized prior to analysis and only aggregate data were reported. For patients who received therapy in this study, informed consent was obtained prior to therapy being performed.
Conflict-of-interest statement: We have no financial relationships to disclose.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Chee-Kiat Tan, MBBS, MRCP, Associate Professor, Department of Gastroenterology and Hepatology, Level 3, Academia, 20 College Road, Singapore 169856, Singapore. tan.chee.kiat@singhealth.com.sg
Telephone: +65-62223322 Fax: +65-62273623
Received: January 15, 2017
Peer-review started: January 15, 2017
First decision: March 16, 2017
Revised: March 28, 2017
Accepted: May 9, 2017
Article in press: May 9, 2017
Published online: June 14, 2017
Peer-review started: January 15, 2017
First decision: March 16, 2017
Revised: March 28, 2017
Accepted: May 9, 2017
Article in press: May 9, 2017
Published online: June 14, 2017
Core Tip
Core tip: This is a retrospective study of Barcelona Clinic Liver Cancer (BCLC) and Hong Kong Liver Cancer (HKLC) staging systems when applied to a multiethnic Asian cohort, where Chinese ethnicity and hepatitis B aetiology are predominant. BCLC was more accurate in directing therapy, with a significantly higher proportion of patients assigned to curative therapy receiving the recommended curative treatment (85.8% vs 61.1%, P < 0.001). Median overall survival in patients assigned to curative therapy by the BCLC and HKLC staging systems was 6.1 and 2.6 years respectively (P < 0.001). Thus, overall, BCLC performed better than HKLC for staging our cohort of patients.